Current Positions: Dr. Chisolm is currently Vice Chairman of the Lerner Research Institute of Cleveland Clinic, where he is a Professor of Cell Biology. He also holds active secondary professorships in the Cleveland Clinic Lerner College of Medicine (CCLCM) of Case Western Reserve University, Kent State University and Cleveland State University. He is also Director of Cleveland Clinic’s Innovation Management and Conflict of Interest Program.
Education: He received a BS from the University of Pennsylvania (Philadelphia), PhD from the University of Virginia (Charlottesville) and postdoctoral research training from the Karolinska Institute (Stockholm) and Massachusetts Institute of Technology (Cambridge).
Research: Dr. Chisolm has published over 110 scientific articles, most on vascular biology and the cell biology of atherosclerosis. His work and contemporaneous studies from others led to the theory that oxidation of low density lipoprotein, LDL, accelerates atherosclerosis.
His laboratory continues to study oxidized LDL's influence on gene expression, programmed cell death, cell proliferation, pro-coagulation processes and “foam cell” formation. His research funding has come predominantly from multiple grants from the NIH, the American Heart Association and the pharmaceutical industry. Dr. Chisolm received the Research Merit Award from the American Heart Association’s Ohio Valley Affiliate (2001) and a Special Recognition Award for Vascular Biology Research from the AHA’s (national) Council on Arteriosclerosis, Thrombosis and Vascular Biology (2006).
Cleveland Clinic (institutional leadership, service, education): Dr. Chisolm has served on Cleveland Clinic’s Board of Governors and Board of Trustees. He is actively involved in numerous aspects of Cleveland Clinic’s new medical school, the CCLCM. He is co-director of the school’s Basic Science Curriculum and sits on the Admissions, Faculty Appointments and Promotions, Student Promotion and GI Curriculum committees. He is recipient of the 2007 Lerner Research Institute Award for Excellence in Education.
Conflict of Interest: Dr. Chisolm is Director of Cleveland Clinic’s Innovation Management and Conflict of Interest Program, Chairman of the IM&CoI Committee and a member of the Clinic’s Board of Trustees CoI Committee. He played an active role in crafting the Clinic’s current CoI policies. He is on the Steering Committee for the Association of American Medical College Forum on Conflict of Interest in Academe and in 2006 hosted at Cleveland Clinic the annual national meeting of this organization and another national summit on CoI (9/06). He has been on the program planning committees for the Forum’s national meetings sponsored by Johns Hopkins University School of Medicine (9/07) and Mayo Clinic (9/08). He was a member of the joint AAMC-AAU Advisory Committee on Conflicts of Interest in Human Subjects Research that recently published updated CoI guidelines. He is a member of CWRU’s CoI Committee and CWRU’s President’s Committee on CoI Policy Development.
American Heart Association: Dr. Chisolm has served the AHA at the regional and national level in numerous committees, task forces and as an officer. He has, for example, served as a member of the Board of Trustees and Board of Directors of regional affiliates, as the President of the regional affiliate, on multiple research peer-review study sections, including as chairman, at the regional and national level. He is an active member and recent officer of the AHA’s Council on Arteriosclerosis, Thrombosis and Vascular Biology.
NIH and Other National Committees: He has served on multiple NIH committees, including the NHLBI Study Section for Program Projects (Chair), the Metabolism Study Section, and the Data Management and Safety Board for the "Arterial Disease Multiple Intervention Trial". He is a member of multiple professional societies.
Editorial Boards and manuscript review: Dr. Chisolm has served as Associate Editor or on the Editorial Board of American Journal of Physiology: Heart and Circulatory Physiology, Arteriosclerosis, Thrombosis and Vascular Biology, and Journal of Biological Chemistry. He has been an ad hoc reviewer for over forty scientific journals.